Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review

被引：0
|
作者：
Mercedes Kile
Patcharaporn Sudchada
机构：
[1] University of Wisconsin-Madison,School of Pharmacy
[2] Naresuan University,Faculty of Pharmaceutical Sciences
来源：
International Urology and Nephrology | 2021年 / 53卷
关键词：
Chronic kidney disease; Anemia; Iron; ESA; Hypoxia-inducible factor prolyl hydroxylase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：283 / 290
页数：7
相关论文
共 50 条
  • [21] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD
    Gupta, Nupur
    Wish, Jay B.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 69 (06) : 815 - 826
  • [22] EFFICACY AND SAFETY OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATMENT OF ANAEMIA OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW
    Atzinger, C.
    Cichewicz, A.
    Huelin, R.
    Alexandre, A. F.
    VALUE IN HEALTH, 2022, 25 (12) : S25 - S25
  • [23] Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in chronic kidney disease patients with renal anemia: a retrospective study
    Odajima, Kohei
    Arai, Shigeyuki
    Kido, Ryo
    Anzai, Hitoshi
    Gojo, Maika
    Taira, Shuntaro
    Matsui, Rena
    Fujigaki, Yoshihide
    Shibata, Shigeru
    BMC NEPHROLOGY, 2024, 25 (01)
  • [24] Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease
    del Balzo, Ughetta
    Signore, Pierre E.
    Walkinshaw, Gail
    Seeley, Todd W.
    Brenner, Mitchell C.
    Wang, Qingjian
    Guo, Guangjie
    Arend, Michael P.
    Flippin, Lee A.
    Chow, F. Aisha
    Gervasi, David C.
    Kjaergaard, Christian H.
    Langsetmo, Ingrid
    Guenzler, Volkmar
    Liu, David Y.
    Klaus, Steve J.
    Lin, Al
    Neff, Thomas B.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 374 (02): : 342 - 353
  • [25] Updates on hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of renal anemia
    Li, Jing
    Haase, Volker H. H.
    Hao, Chuan-Ming
    KIDNEY DISEASES, 2023, 9 (01) : 1 - 11
  • [26] Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
    Ogata, Masatomo
    Miyauchi, Takamasa
    Sakurai, Yuko
    Murata, Marie
    Shinoda, Kazunobu
    Shibagaki, Yugo
    Yazawa, Masahiko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (05) : 1024 - 1026
  • [27] Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats
    Charles, Samuel
    Suessenberger, Ricarda
    Settje, Terry
    Langston, Catherine
    Lainesse, Chantal
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2024, 38 (01) : 197 - 204
  • [28] ROXADUSTAT Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of Anemia
    Virgili-Lopez, G.
    DRUGS OF THE FUTURE, 2014, 39 (11) : 783 - 791
  • [29] Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
    Ren, Song
    Yao, Xiaoxiu
    Li, Yi
    Zhang, Ying
    Tong, Chao
    Feng, Yunlin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [30] Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia
    Nakanishi, Takeshi
    Kuragano, Takahiro
    CLINICAL KIDNEY JOURNAL, 2024, 17 (03)
12345